Keylika

Executive Summary

Keylika is a San Francisco-based biotech company founded in 2020 that leverages AI-enabled de novo drug design and nanotechnology-based transdermal delivery to create best-in-class therapies. Its lead program targets iron deficiency anemia (IDA) with the world's first Rx skin patch, addressing a critical unmet need in drug delivery. By combining computational drug discovery with advanced transdermal platforms, Keylika aims to improve patient compliance and therapeutic outcomes. The company operates at the intersection of drug discovery and delivery, a strategy that could differentiate it in the competitive anemia space. However, limited public information on funding, pipeline, or regulatory progress constrains visibility. Keylika's focus on a novel modality for a common condition positions it for potential partnerships or clinical milestones in the near future.

Upcoming Catalysts (preview)

• Q4 2026Series A or Seed Extension Financing70% success
• Q1 2027Preclinical Proof-of-Concept Data for IDA Patch60% success
• Q2 2027IND Filing or Investigational New Drug Application50% success